Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Krystal Biotech (NASDAQ:KRYS) released its quarterly earnings results on Wednesday. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23, Zacks reports. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%.

Krystal Biotech Trading Up 2.3 %

Shares of Krystal Biotech stock opened at $156.69 on Wednesday. The stock has a 50-day moving average price of $157.98 and a 200 day moving average price of $175.42. The company has a market cap of $4.51 billion, a P/E ratio of 88.53 and a beta of 0.84. Krystal Biotech has a 1 year low of $107.50 and a 1 year high of $219.34.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 14.10% of the company’s stock.

Wall Street Analysts Forecast Growth

KRYS has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Wednesday, December 18th. Citigroup raised their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus target price of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).